

After gathering public comments for the 2011 [ANPRM](#) and the 2015 [NPRM](#), the [final rule](#) updating the [Federal Policy for the Protection of Human Subjects](#) ("The Common Rule") was published in January 19, 2017. The revisions are intended: to better protect human subjects involved in research, facilitate research, remove ambiguity, and reduce regulatory burden.

Definition of Human Subjects

Human subject means a living individual about whom an investigator conducting research:

- Obtains information *or biospecimens* through intervention or interaction with the individual, and uses, studies, or analyzes the information *or biospecimens*; or
- Obtains, uses, studies, analyzes, or generates identifiable private information *or identifiable biospecimens*

Definition of Research

The Common Rule now provides 4 examples of types of activities that in general would **not** constitute research:

- [Scholarly/Journalistic activities](#)
- [Public Health Surveillance](#)
- [Collection/analysis of information/biospecimen/records for/by a criminal justice agency](#)
- [Authorized operational activities by an agency for intelligence, homeland security, defense, or national security missions](#)

Vulnerable Population

- Pregnant women and handicapped/mentally disabled populations are **no** longer considered vulnerable.
- Individuals with impaired decision-making capacity and economically/educational disadvantaged **are** considered vulnerable population.

Informed Consent will require additional information (when applicable) *

- [Begin with a concise presentation of the key information](#) that would facilitate comprehension.
- Specific language regarding future research for [studies that involves collection of identifiable private information or identifiable specimens](#)
- A statement when specimens may be used for [commercial profit](#)
- A statement when [clinically relevant research results](#) will be disclosed to subjects
- A statement when [whole genome sequencing](#) may be performed
- For the storage, maintenance, and secondary research use of identifiable private information or identifiable biospecimens, the [broad consent must contain 7 key elements](#)
- Adequate [provisions to protect privacy of subjects / maintain confidentiality of data](#) (DHHS guidance is forthcoming.)

Screening, recruiting, and determining eligibility

An IRB may approve a research proposal in which an investigator will obtain information or biospecimens for the purpose of screening, recruiting, or determining the eligibility of prospective subjects *without the informed consent of the prospective subject (or the subject's legally authorized representative)* **when either of these conditions are met:**

- The investigator will obtain information through oral or written communication with the prospective subject or legally authorized representative, or
- The investigator will obtain identifiable private information or identifiable biospecimens by accessing records or stored identifiable biospecimens

Posting of clinical trial consent form *

A copy of the template consent form must be posted on a federal website after the clinical trial (*sponsored by a federal department or agency*) is closed to recruitment and no later than 60 days after the last study visit by any subject. (DHHS guidance is forthcoming.)

NOTES:

* The [Department of Justice \(DOJ\)](#) and the [Food and Drug Administration \(FDA\)](#) have not yet adopted the revised Common Rule.

The [Federal Policy for the Protection of Human Subjects](#) will not affect any state/local laws or regulations, including tribal law passed by the official governing body of an [American Indian or Alaska Native tribe](#)